Clinical trials: Angina Patients With Non-obstructive Coronary Artery Disease
Refractory Angina, Microvascular Angina
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.
To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic…
- Conditions
- Refractory Angina, Microvascular Angina, Microvascular Coronary Artery Disease, Coronary Disease
- Trial name
- REMEDY-PILOT (NCT05492110)
- Testing
- Coronary sinus reducer, Invasive coronary physiology
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Imperial College London
Angina Patients With Non-obstructive Coronary Artery Disease
Exercise Therapy for Women With ANOCA
Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat…
- Trial name
- ANOCA Exercise (NCT07733986)
- Testing
- Resistance based exercise
- Where
- 11 sites in United Kingdom
- Volunteers
- 76 people
- Sponsor
- NHS Greater Glasgow and Clyde
Angina, Non-obstructive Coronary Artery Disease
Imaging Coronary Microvascular Dysfunction (CMD) Study
Angina is a common clinical symptom of ischemic heart disease, affecting up to 11 million people in the United States alone, and 112 million people globally.
- Trial name
- NCT05634031
- Testing
- PET imaging, Coronary CT angiogram, Functional Angiography
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Angina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain
Long Covid-19 INOCA is an investigator-initiated, prospective, randomized, sham-controlled, single center study. Its objective is to investigate the benefits of tailored medical therapy according to the results of the coronary…
- Conditions
- Angina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Long COVID-19 Syndrome
- Trial name
- NCT07559994
- Testing
- Coronary functional test
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women.
- Conditions
- Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
- Trial name
- STRONG (NCT06600178)
- Testing
- Brenzavvy (bexagliflozin), 20 mg Oral Tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Virginia
Myocardial Infarction With Non-Obstructive Coronary Arteries
Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).
The aim of our study is to evaluate if the use of a precision-medicine approach with a specific therapy tailored on the underlying pathogenic mechanism will improve the quality-of-life in MINOCA patients.
- Trial name
- PROMISE (NCT05122780)
- Testing
- Coronary angiography, OCT imaging, Percutaneous coronary intervention (PCI):
- Where
- 3 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)
The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary…
- Conditions
- Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Index of Microvascular Resistance
- Trial name
- NCT06503640
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China-Japan Friendship Hospital
Microvascular Angina, Vasospastic Angina
Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries
In patients with angina pectoris undergoing a coronary angiography (CAG) up to 40% do not have obstructive coronary artery disease (CAD).
- Trial name
- TENS-ANOCA (NCT06401291)
- Testing
- Transcutaneous Electrical Nerve Stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Angina Attacks, Non Obstructive Coronary Artery Disease
The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)
The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA).
- Trial name
- NANA (NCT06890507)
- Testing
- N-Acetylcysteine (NAC)
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- University of Adelaide
Angina Pectoris, Variant, Angina Pectoris; Spasm-Induced
ReACHallenge Trial: Acetylcholine Rechallenge After Pretreatment With Vasoactive Drugs
The goal of this clinical trial is to assess the feasibility and clinical value of acetylcholine (ACH) rechallenge after intracoronary verapamil +- nitroglycerine in a patient cohort with angina and non-obstructive coronary…
- Conditions
- Angina Pectoris, Variant, Angina Pectoris; Spasm-Induced, Angina Pectoris With Normal Coronary Arteriogram
- Trial name
- ReACHallenge (NCT05618132)
- Testing
- Acetylcholine rechallenge
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- University Hospital, Antwerp
Coronary Artery Disease, Microvascular Angina
Standardizing the Management of Patients With Coronary Microvascular Dysfunction
The SAMCRO is an all comers, prospective, randomized, multicenter, open-label study with blinded adjudicated evaluation of outcomes (PROBE).
- Conditions
- Coronary Artery Disease, Microvascular Angina, Microvascular Ischemia of Myocardium
- Trial name
- SAMCRO (NCT06025994)
- Testing
- MULTI-DOMAIN LIFESTILE INTERVENTION
- Where
- 2 sites in Italy
- Volunteers
- 123 people
- Sponsor
- Consorzio Futuro in Ricerca
ANOCA, ANOCA - Angina With Non-obstructive Coronary Arteries
Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic
Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of…
- Conditions
- ANOCA, ANOCA - Angina With Non-obstructive Coronary Arteries, MINOCA, Microvascular Dysfunction
- Trial name
- CoroPhys-CZ (NCT07103317)
- Where
- Czechia
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Motol
Coronary Artery Disease, Microcirculation Resistance
COronoary Microcirculation Analysis NETwork
COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving…
- Conditions
- Coronary Artery Disease, Microcirculation Resistance, Microcirculation; Biomarkers; Myocardial Ischemia, Microcirculatory Dysfunction
- Trial name
- COMA-NET (NCT07498231)
- Testing
- Coronary microvascular function assessment
- Where
- Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Bialystok
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
The goal of this prospective study is to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA.
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Insulin Resistance
- Trial name
- IRIN (NCT06597851)
- Testing
- Thermodilution based assessment of coronary microcirculation, Hyperinsulinemic-euglycemic Clamp test
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Coronary Microvascular Dysfunction, Microvascular Angina
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
EXAMINE-CAD-DZHK22 is a prospective, randomized, double-blind, placebo-controlled, crossover trial investigating the efficacy of beta blocker (bisoprolol) and calcium channel blocker (diltiazem) therapy in symptomatic patients…
- Conditions
- Coronary Microvascular Dysfunction, Microvascular Angina, Vasospasm, Coronary, Vasospastic Angina
- Trial name
- EXAMINE-CAD (NCT05294887)
- Testing
- Bisoprolol, Diltiazem
- Where
- 15 sites in Germany, Switzerland
- Volunteers
- 132 people
- Sponsor
- Charite University, Berlin, Germany
Angina (Stable), Percutaneous Coronary Intervention (PCI)
Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography
AID Post-PCI Angina is as an observational, prospective, single-cohort, multicenter study designed to investigate the causes and origins of post-PCI angina by using the advance invasive diagnosis (AID) strategy combining with…
- Conditions
- Angina (Stable), Percutaneous Coronary Intervention (PCI), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Chronic Coronary Syndrome
- Trial name
- NCT07638137
- Testing
- An advanced invasive diagnosis (AID) strategy combining with angiography derived physiology (ADP)
- Where
- 5 sites in Spain
- Volunteers
- 246 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Chest Pain, Ischemia
Evaluation of Patients With Non-obstructive Coronary Arteries
Patients with angina and non-obstructive CAD are common within clinical practice, but remain a challenge with regard to diagnosis and treatment.
- Trial name
- noCAD (NCT00823563)
- Testing
- 30 cc blood draw, Intravascular ultrasound (IVUS), Coronary pressure/flow wire testing
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Stanford University
Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease
Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA
The purpose of this study is to see if inorganic nitrate in the form of beetroot juice helps blood flow and physical fitness in women with ANOCA and CMD.
- Trial name
- NO-ANOCA (NCT06948201)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Virginia
Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio.
- Conditions
- Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina
- Trial name
- LESS (NCT04897126)
- Testing
- Shexiang Baoxin pill（MUSKARDIA）
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited